INTRODUCTION {#S1}
============

Dopamine (DA) release in the dorsal striatum (DS) is a critical component of reinforcement ([@R2]). Midbrain DA neuron phasic firing correlates with discrepancies between reward expectation and outcome and is hypothesized to facilitate reinforcement learning, as described by the reward prediction error model ([@R37]). Single-unit recordings in the area of the midbrain that projects to the DS, the substantia nigra pars compacta, reveal DA neuron burst firing that corresponds with the start and stop of action sequences ([@R23]), as well as movement kinematics ([@R3]; [@R13]).

At the level of the DA neuron terminal field in the DS, parallel phasic changes in DA release relate to reward and action execution ([@R19]; [@R20]; [@R36]). Diverging from DA neuron somatic activity, however, phasic increases in DA release correlate with reward anticipation ([@R17]). Moreover, striatal DA release ramps up as a function of spatial proximity to a reward and scales to changes in the length of a maze that is required to be traversed to obtain a reward ([@R21]). Whereas DA neuron firing rates ramp up only when reward reinforcement is uncertain ([@R15]), increases in DA release persists in sessions in which reward is guaranteed ([@R21]). Altogether, these accounts of diverse activity across DA neuron soma and axon terminals suggest the existence of behaviorally relevant DA release mechanisms acting at the level of the DA neuron terminal field ([@R5]).

Supporting this notion, electrical stimulation of non-selective thalamic inputs to the striatum drives cholinergic interneurons to burst fire and subsequently pause their firing in a DA D2 receptor-dependent manner ([@R11]). Because this so-called burst-pause activity of cholinergic neurons is associated with learning ([@R1]), these data collectively suggest that the intralaminar nuclei of the thalamus may direct cholinergic interneuron activity *in vivo* to shape action learning through local striatal DA release mechanisms ([@R47]). DA release is observed in both the dorsal and the ventral striatum following synchronous cholinergic interneuron activation ([@R7]; [@R29]; [@R41]). Because of the innervation of cholinergic interneurons by the parafascicular thalamic intralaminar nucleus (Pf), activation of this structure elicits local striatal DA release in a nicotinic acetylcholine receptor-dependent manner ([@R41]).

In addition to the Pf, the rostral intralaminar nuclei of the thalamus (rILN), consisting of the tightly bundled central lateral, paracentral, and central medial nuclei, similarly projects to the striatum ([@R4]; [@R22]). This raises the possibility that rILN activity may influence striatal DA release. rILN projections to the DS facilitate incubation of methamphetamine craving in a DA D1 receptor-dependent manner ([@R28]). Here, we find that rILN terminal activation in DS slices drives DA-dependent cholinergic interneuron burst-pause activity and, accordingly, evokes DS DA release in an acetylcho-line-dependent manner. *In vivo*, we report that suppressing rILN activity modulates dopaminergic nigrostriatal terminal activity and that optogenetic stimulation of rILN terminals facilitates intracranial self-stimulation in a D1 receptor-dependent manner. We also present evidence that cholinergic interneurons contribute to this behavior. These results underscore the potential for non-canonical, local striatal release mechanisms in mediating reward-related behaviors.

RESULTS {#S2}
=======

The rILN Elicits Local Striatal DA Release through Cholinergic Interneurons {#S3}
---------------------------------------------------------------------------

To determine whether rILN activation elicits striatal DA release through a cholinergic interneuron-dependent mechanism, we first explored whether rILN terminals innervate cholinergic interneurons in the DS. We expressed channelrhodopsin (ChR2)-enhanced yellow fluorescent protein (eYFP) in the rILN ([Figure S1](#SD1){ref-type="supplementary-material"}) and optogenetically activated ChR2-expressing rILN terminals while recording from cholinergic interneurons using whole-cell patch-clamp electrophysiology ([Figures 1A--1D](#F1){ref-type="fig"}). We observed characteristic tonic firing in tdTomato-labeled neurons ([Figure 1E](#F1){ref-type="fig"}). Activation of rILN terminals with single blue light pulses evoked post-synaptic currents evoked by optogenetic activation (oPSCs) that were abolished in the presence of AMPA and NMDA receptor antagonists, NBQX and AP5, respectively (t(8) = 8.56, p \< 0.0001) ([Figure 1F](#F1){ref-type="fig"}).

To examine whether rILN afferents in the DS sufficiently innervate cholinergic interneurons to elicit burst action potential firing followed by the characteristic DA-dependent pause in firing behavior ([@R11]), we recorded from cholinergic interneurons in current-clamp mode while optogenetically activating rILN afferents. We found that a 1.5 s light pulse train induced a burst-pause firing response in cholinergic interneurons ([Figure 1G](#F1){ref-type="fig"}). The time to first action potential following the burst response was significantly greater than the pre-burst interspike interval (ISI) (p = 0.001) ([Figure 1H](#F1){ref-type="fig"}). To determine whether the post-burst pause was DA mediated, we applied the D2 receptor antagonist sulpiride ([Figure 1I](#F1){ref-type="fig"}). Sulpiride produced a trending, but not significant, increase in the baseline firing rate (p = 0.11) ([Figure 1J](#F1){ref-type="fig"}) but no difference in burst response (p = 0.85) ([Figure 1K](#F1){ref-type="fig"}) compared with control recordings. Sulpiride incubation significantly shortened the post-burst pause in firing (p = 0.005) ([Figure 1L](#F1){ref-type="fig"}) and decreased the post-burst ISI to the baseline ISI ratio (p = 0.028) ([Figure 1M](#F1){ref-type="fig"}).

The DA-modulated burst-pause firing behavior we observed in striatal slice suggests that rILN afferent activation leads to local DA release. To provide direct evidence of this, we used fast-scan cyclic voltammetry (FSCV) to measure electrical currents derived from DA transients. Optogenetic activation of rILN terminals in acute striatal slices evoked transient DA release in the DS ([Figures 2A and 2B](#F2){ref-type="fig"}). DA release persisted across repeated light pulses, decaying to an average 73.7% ± 7.1% of baseline (t(7) = 3.69, p = 0.0078) and was eliminated by NBQX (compared to control recordings: t(14) = 9.86, p \< 0.0001; compared to NBQX baseline: t(7) = 64.69, p \< 0.0001) ([Figure 2C](#F2){ref-type="fig"}), but not by AP5, of which current decayed to 79.0% ± 7.3% of baseline (compared to control: t(14) = 0.52, p = 0.61; compared to AP5 baseline: t(7) = 2.87, p = 0.02) ([Figure 2D](#F2){ref-type="fig"}). The nicotinic receptor antagonist mecamylamine also abolished optogenetically evoked DA release (compared to control: t(14) = 10.31, p \< 0.0001; compared to mecamylamine baseline: t(7) = 1009, p \< 0.0001) ([Figure 2E](#F2){ref-type="fig"}). To confirm that the recorded current was DA derived, and not serotonin, for example, we applied the D2 receptor agonist quinpirole to activate DA autoreceptors. Quinpirole significantly attenuated the light-evoked current compared to the control condition (t(13) = 9.61, p \< 0.0001) ([Figure 2F](#F2){ref-type="fig"}).

rILN Activity Modulation of Nigrostriatal Terminal Activity and Movement {#S4}
------------------------------------------------------------------------

Because rILN terminal activation robustly elicits local DA release, we next sought to determine whether the rILN provides an ongoing modulation of dopaminergic nigrostriatal terminal activity *in vivo*. To this end, we employed fiber photometry to monitor nigrostriatal terminal activity ([@R32]) while chemogenetically suppressing rILN activity. To first validate the efficacy of inhibitory DREADD receptor hM4Di-mediated suppression of glutamate release from rILN into the DS, we co-expressed ChR2-eYFP and hM4Di-mCherry in the rILN and recorded oPSC events in medium spiny neurons (MSNs) in acute striatal slices ([Figure 3A](#F3){ref-type="fig"}). Activating hM4Di receptors with clozapine-N-oxide (CNO) reduced oPSC amplitude to 44.5% ± 5.2% of baseline compared to control artificial cerebral spinal fluid (aCSF) with an amplitude of 98.4% ± 11.7% (t(13) = 3.57, p = 0.0034; compared to CNO baseline: t(5) = 10.60, p = 0.0001) ([Figure 3B](#F3){ref-type="fig"}).

We next used fiber photometry to monitor population-level, activity-dependent calcium transients arising from GCaMP6f-expressing dopaminergic nigrostriatal terminals in mice. These mice also expressed either hM4Di-mCherry or mCherry fluorophore alone in the rILN and were unilaterally implanted with a multimode fiber in the DS ([Figure 3C](#F3){ref-type="fig"}). CNO administration significantly reduced the GCaMP6f peak signal in hM4Di-expressing mice, but not mCherry-expressing mice, compared with vehicle in freely moving mice ([Figures 3D and 3E](#F3){ref-type="fig"}). Two-way ANOVA showed main effects for the drug (F~1,28~ = 11.53, p = 0.0021), the animal group (F-~1,28~ = 5.78, p = 0.023), and a significant interaction (F-~1,28~ = 5.78, p = 0.023) of the two factors. The off-peak spectral channel photon count, which is subtracted from the GCaMP6f-associated channel to derive the peak signal, did not differ significantly before or after CNO administration in either group (group: F~1,27~ = 1.618, p = 0.214; drug: F~1,27~ = 3.42, p = 0.076; interaction: F~1,27~ = 3.48, p = 0.073). The change in nigrostriatal activity-dependent calcium activity was accompanied by significant reductions in movement in hM4Di-expressing mice, but not mCherry-expressing mice, as measured by total distance moved (drug: F~1,28~ = 2.95, p = 0.097; group: F~1,28~ = 2.87, p = 0.095; interaction: F~1,28~ = 11.12, p = 0.0024) ([Figure 3F](#F3){ref-type="fig"}), maximum velocity achieved (drug: F~1,28~ = 2.13, p = 0.16; group: F~1,28~ = 0.62, p = 0.44; interaction: F~1,28~ = 8.15, p = 0.008) ([Figure 3G](#F3){ref-type="fig"}), and percentage of time in motion (drug: F~1,28~ = 2.66, p = 0.11; group: F~1,28~ = 5.62, p = 0.025; interaction: F~1,28~ = 8.99, p = 0.0057) ([Figure 3H](#F3){ref-type="fig"}) during a 5 min period.

rILN → DS Pathway Activation Is Behaviorally Reinforcing {#S5}
--------------------------------------------------------

Because DS DA is associated with behavioral reinforcement ([@R14]; [@R35]), we next investigated whether activation of rILN inputs into the DS supports reinforcement in a DA-dependent manner. To test this, we trained mice in an optical intracranial self-stimulation (oICSS) paradigm ([Figure 4A](#F4){ref-type="fig"}). Mice expressing ChR2-eYFP in the rILN lever pressed for light activation of rILN → DS terminals significantly more than the non-reinforced lever and reliably switched lever preference when light delivery was reversed to the opposite lever 24 h later ([Figure 4B](#F4){ref-type="fig"}). Because rILN-dependent incubation of drug craving is mediated by DS DA D1 receptors ([@R28]), we investigated whether D1 receptor activity was necessary for oICSS. We found that administration of the D1 receptor antagonist SCH23390 before oICSS sessions significantly reduced this preference for the light-paired lever, as did sessions in which neither lever was paired with light delivery. Within-subject two-way ANOVA showed a main effect of the lever on day 2 (F~1,8~ = 54.41, p \< 0.0001), not day 1 (F~1,8~ = 4.12, p = 0.077); main effects for the condition (day 1: F~3,24~ = 6.24, p = 0.003; day 2: F~3,24~ = 9.96, p = 0.0002); and significant interactions (day 1: F~3,24~ = 14.02, p \< 0.0001; day 2: F~3,24~ = 20.90, p \< 0.0001). In contrast, mice expressing eYFP alone in the rILN did not demonstrate a preference for the light-paired lever ([Figure 4C](#F4){ref-type="fig"}). Analysis of the lever and condition showed the main effects for the lever (day 1: F~1,8~ = 9.17, p = 0.016; day 2: F~1,8~ = 12.74, p = 0.007); the main effect of the condition for day 2 (F~3,24~ = 5.60, p = 0.005), not day 1 (F~3,24~ = 1.84, p = 0.167); and no significant interaction between the two factors for either day (day 1: F~3,24~ = 1.156, p = 0.347; day 2: F~3,24~ = 0.227, p = 0.877). Assessing the effect of light delivery and drug administration on total press rates, ChR2-eYFP mice pressed significantly more during light-reinforced sessions following vehicle administration (Veh+Light) than in any other condition, whereas eYFP mice demonstrated no significant differences in total press rates between the conditions ([Figure S2](#SD1){ref-type="supplementary-material"}). Moreover, total press rates between the two animal groups only differed significantly in the Veh+Light condition. Significant effects were found in the condition (day 1: F~3,48~ = 7.8, p = 0.0003; day 2: F~3,48~ = 14.6, p \< 0.0001), the animal group (day 1: F~1,16~ = 3.0, p = 0.102; day 2: F~1,16~ = 14.4, p = 0.0016), and an interaction of the two factors (day 1: F~3,48~ = 7.8, p \< 0.001; day 2: F~3,48~ = 4.06, p = 0.012).

Because the rILN projects to MSNs ([@R12]), we next examined whether the rILN → cholinergic interneuron circuit is required for rILN-evoked behavioral reinforcement by ablating cholinergic interneurons at the site of light delivery with a viral taCasp3 construct ([Figure 4D](#F4){ref-type="fig"}). Compared to a control cohort of mice injected with DIO-mCherry in the striatum, taCasp3 mice failed to demonstrate a preference for the light-paired lever on the first test day (lever: F~1,11~ = 10.14, p = 0.0087; animal group: F~1,11~ = 0.62, p = 0.45; interaction: F~1,11~ = 5.61, p = 0.037) ([Figure 4E](#F4){ref-type="fig"}, left). Upon lever reversal, however, taCasp3 mice performed similarly to mCherry controls by pressing the light-paired lever significantly more than the non-reinforced lever (lever: F~1,11~ = 37.15, p \< 0.0001; animal group: F~1,11~ = 0.81, p = 0.39; interaction: F~1,11~ = 0.67, p = 0.43) ([Figure 4E](#F4){ref-type="fig"}, right).

Pf → DS Pathway Activation Evokes a Transient DA Response {#S6}
---------------------------------------------------------

To understand how rILN-evoked striatal DA release and behavior compare with those of Pf inputs, we injected ChR2-eYFP in the Pf. We found that optogenetic activation of Pf terminals evoked DS DA release ([Figures S3A and S3B](#SD1){ref-type="supplementary-material"}), confirming findings by [@R41]. This DA response decayed significantly over time compared to rILN-evoked release ([Figure S3C](#SD1){ref-type="supplementary-material"}). Analyzing evoked current normalized to the first time point, there were significant main effects of time (F~9,198~ = 25.88, p \< 0.0001) and thalamic region (F~1,22~ = 36.42, p \< 0.0001), with a significant interaction (F~9,198~ = 9.61, p \< 0.0001). Pf-evoked DA release was attenuated by mecamylamine compared to control (t(11) = 4.39, p = 0.0011) ([Figure S3D](#SD1){ref-type="supplementary-material"}) ([@R41]). We then assessed whether Pf-evoked DA release is behaviorally reinforcing. Mice expressing ChR2-eYFP in Pf did not prefer to press the lever paired with bilateral DS light delivery on the first test day compared to the non-reinforced lever. Although mice pressed the light-paired lever more upon lever reversal on day 2 ([Figure S3E](#SD1){ref-type="supplementary-material"}), two-way ANOVA did not reveal main effects for the lever (F~1,6~ = 1.35, p = 0.29), the day (F~1,6~ = 1.28, p = 0.30), or an interaction of the two factors (F~1,6~ = 4.82, p = 0.07).

DISCUSSION {#S7}
==========

These data support the notion that the rILN → DS pathway activates cholinergic interneurons to drive local DA release from nigrostriatal terminals and that activity of this thalamostriatal pathway is associated with nigrostriatal terminal activity *in vivo*. These data show that local striatal DA release is sufficient to support behavioral reinforcement.

Although the rILN has not been studied in depth, [@R28] demonstrated rILN → DS-mediated incubation of drug seeking that supports a role for this thalamic region in reward-related behavior. Given that the rILN is innervated by sensory processing structures ([@R42]), this pathway may relay salient sensory cues to inform actions. Furthermore, specific rILN → DS projections are linked to movement kinematics ([@R9]), as well as behavioral flexibility and attentional set shifting ([@R24]). Altogether, the Pf and rILN likely act in concert to shape striatal DA signals and thus mediate an action response to reward-related cues.

Our finding that cholinergic interneuron ablation disrupted behavioral reinforcement on the first test day suggests that rILN-evoked behaviors may be mediated through the combination of rILN synapses on other striatal cell populations to facilitate the behavioral reinforcement observed on the second test day. Alternatively, the day 2 lever-pressing effect may arise from plastic changes at rILN → MSN synapses that developed in the absence of cholinergic interneurons. Future work is necessary to determine the possible contribution of rILN → MSN synapses in supporting behavioral reinforcement in a DA- and acetylcholine-independent manner.

A comparison of rILN and Pf projections to DS suggests that they have distinct axon morphology, axo-dendritic connections ([@R27]), and plasticity mechanisms ([@R12]). Together with possible activation of the presynaptic mGluR2/3 and D2 autoreceptors on thalamic and nigrostriatal afferents, respectively, rILN projections may uniquely synapse on cholinergic interneurons to support the observed differences in DA release compared to Pf afferents. Mice exhibited a preference (although not a significant one) for Pf stimulation upon lever reversal on day 2, which is reminiscent of Pf → cholinergic interneuron pathway-mediated reversal learning ([@R6]).

Combined with potential cholinergic interneuron → nigrostriatal terminal and Pf → cholinergic interneuron → nigrostriatal terminal pathways, our presently described rILN → cholinergic interneuron → nigrostriatal terminal circuit reveals another possible local DS DA release pathway. This suggests that somatic activity is only one contributor to DA release and approaches that exclusively examine this dimension may not fully capture the dynamic signaling occurring at the striatal level that guides behavior ([@R5]). Nigrostriatal axons extensively arborize; a single neuron gives rise to an estimated 1 million synapses ([@R30]; [@R33]). Local axo-axonic circuits may thus provide more spatially restricted DA signaling that may be driven by associative thalamic structures encoding salient sensory information. Cortical afferent stimulation also evokes DA release in striatal slices through cholinergic interneuron activation ([@R25]; [@R29]), which further suggests that axo-axonic synapses for local DS DA release are a recurring theme. These synaptic configurations are frequently observed in electron microscopy studies, including in the DS([@R40]).

The expanse of pathologies involving DA dysfunction potentially implicate the rILN → DS circuit in various neuropsychiatric disorders. The degeneration of the nigrostriatal pathway in Parkinson's disease is associated not only with motor dysfunction ([@R46]) but also motivational deficits ([@R34]) and cognitive deficits ([@R18]). Degeneration of thalamostriatal projections is reported in Parkinson's disease ([@R16]; [@R39]), which suggests that loss of rILN → DS-mediated DA signaling may contribute to disease symptomology ([@R31]). Furthermore, aberrant DS DA transmission is implicated in both attention deficit/hyperactivity disorder ([@R10]; [@R43]) and drug abuse ([@R44]). Investigating how the rILN → DS circuit contributes to these disease states stands to reveal targets for therapeutic intervention.

STAR★METHODS {#S8}
============

Detailed methods are provided in the online version of this paper and include the following:

CONTACT FOR REAGENT AND RESOURCE SHARING {#S9}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Brian Mathur (<bmathur@som.umaryland.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S10}
--------------------------------------

2-4-month-old male and female C57BL/6J (wild-type) mice were given *ad libitum* access to food and water and maintained on a 12:12 h light/dark cycle (lights on at 0700 hr). Mice were housed with littermates (2-5 per cage), except for those singly-housed following fiber implantation. To visually-identify cholinergic interneurons for electrophysiological recordings, ChAT-IRES-Cre mice were crossed in-house with tdTomato reporter mice (Ai9(RCL-tdT) to selectively express tdTomato fluorophore in Cre-recombinase-expressing cholinergic neurons (referred here as "ChAT-tdT"). Heterozygous DAT-IRES-Cre mice (DAT-cre) were used for *in vivo* photometry. All experiments were performed in accordance with the United States Public Health Service Guide for Care and Use of Laboratory and were approved by the Institutional Animal Care and Use Committee at the University of Maryland, Baltimore.

METHOD DETAILS {#S11}
--------------

### Surgical Procedures {#S12}

To virally express ChR2 in the rILN, wild-type mice were stereotaxically injected under isoflurane (5% induction, 1%--2% maintenance) with AAV-hSyn-ChR2-eYFP or control AAV-hSyn-eYFP viruses (See [Figure S1](#SD1){ref-type="supplementary-material"}). Viruses were injected at a volume of 300 nl/side and rate of 20 nl/min in the rILN (relative to bregma in mm, anterior-posterior (AP) −1.4, medial-lateral (ML) ± 0.35, dorsalventral (DV) −3.55) or Pf (250 nL/side; AP −2.5, ML ± 0.75, DV −3.25) with a 25G syringe (Hamilton Company). To virally ablate striatal cholinergic interneurons, AAV5-flex-taCasp3-TEVp (or the control AAV5-EF1a-DIO-mCherry) was bilaterally injected in the striatum (500 nl/side; AP +0.80, ML ± 1.75, DV −2.75) of heterozygous ChAT-cre or ChAt-tdT mice. Four weeks later, manually-constructed optic fibers with high numerical aperture (NA; 0.66) fiber (Prizmatix) were bilaterally implanted in the DS (AP +0.80, ML ± 1.75, DV −2.25) and secured with TitanBond (Horizon) and dental cement. Animals recovered for at least one week prior to behavioral testing.

For *in vivo* photometry, DAT-cre mice were unilaterally injected with AAV5-hSyn-GCaMP6f-FLEX in the substantia nigra at a volume of 450nl at two sites (AP −3.5, ML 1.5, DV −4.75 and AP −3.0, ML 1.5, DV −4.8). These mice also received bilateral injections of AAV8-hSyn-hM4Di-mCherry or control AAV8-hSyn-mCherry in the rILN (as described above). These mice were unilaterally implanted with a low NA (0.22) fiber (ThorLabs) in the DS.

Immunohistochemistry was used to confirm virus expression at injection sites; animals were excluded from experiments for poor virus expression at targeted regions or if virus expression was detected in the Pf for rILN-targeted injections (or rILN-localized expression for Pf-targeted injections).

### Brain Slice Preparation {#S13}

Mice were deeply anesthetized with isoflurane and brains were quickly removed and submerged in 95% oxygen, 5% carbon dioxide (carbogen)-bubbled ice cold cutting solution (in mM): 194 sucrose, 30 NaCl, 4.5 KCl, 1 MgCl2, 26 NaHCO3, 1.2 NaH2PO4, and 10 D-glucose). 250 μm coronal slices were obtained on a Leica VT 1200 vibratome and stored in carbogen-bubbled aCSF (in mM); 124 NaCl, 4.5 KCl, 2 CaCl2, 1 MgCl2, 26 NaHCO3, 1.2 NaH2PO4, and 10 D-glucose). Striatal slices were incubated at 32.4°C for 30 min and stored thereafter at room temperature until recording.

### Whole-cell Electrophysiology {#S14}

Hemisected ChAT-tdTomato brain slices were transferred to the recording chamber and perfused with carbogen-bubbled aCSF (in mM; 124 NaCl, 4.5 KCl, 2 CaCl2, 1 MgCl2, 26 NaHCO3, 1.2 NaH2PO4, and 10 D-glucose) at 29-31°C. Whole-cell recordings were made with glass micropipettes (2-5 mΩ) filled with CsMeSO~3~-based internal solution (in mM; 120 CsMeSO~3~, 5 NaCl, 10 TEA-Cl, 10 HEPES, 5 QX-314, 1.1 EGTA, 4 Mg-ATP, and 0.3 Na-GTP; 290-300 mOsm and pH 7.3) to record oPSCs were evoked with 2-4 ms 473 nm light pulses and recorded in whole-cell voltage clamp. Drugs dissolved in aCSF were delivered to brain slices through a gravity perfusion system. Visually-identified tdTomato-expressing cholinergic interneurons were voltage-clamped at −60 mV with a MultiClamp 700B amplifier (Molecular Devices) and recordings were filtered and digitized at 2 and 10 kHz, respectively. For burst-pause experiments, cholinergic interneurons were recorded in cell-attached or whole cell current-clamp configurations with a K^+^-based internal solution (in mM: 126 potassium gluconate, 4 KCl, 10 HEPES, 4 ATP-Mg, 0.3 GTP-Na, and 10 phosphocreatine; 290-295 mOsm; pH 7.3). Data was acquired with Clampex 10.4.1.4 and analyzed with Clampfit 10.4.1.4 (Molecular Devices). Cells were discarded from analysis if series resistance changed by more than 15% during recording. For voltage-clamp experiments, oPSC amplitudes were averaged per min and expressed as a percent change from baseline measurements (first 5 min of recordings). The averaged baseline was statistically compared with averaged last 5 min of recording.

### FSCV {#S15}

Hemisected brain slices were transferred to the recording chamber and perfused with carbogen-bubbled Krebs buffer (in nM: 126 NaCl, 2.5 KCl, 1.2 NaH2PO4, 2.4 CaCl2, 1.2 MgCl2, 0.4 L-ascorbic acid, 20 HEPES, 10 D-glucose, 25 NaHCO3, and 10 NaOH; pH 7.3 -- 7.4) at 28-30°C. A 7 μm carbon fiber was aspirated into a borosilicate glass capillary tube and pulled on a P-80 horizontal pipette puller (Sutter Instruments). The extended electrode fiber was trimmed to approximately 100 μm. Voltammetry recordings and analysis were performed with TarHeel CV software (University of North Carolina). The electrode potential was linearly scanned as a triangular waveform from −0.4 to 1.3 to −0.4 V (Ag versus AgCl) at 400 V/s. Electrodes were first conditioned by applying the voltage ramp at 60 Hz for 10 min and then 10 Hz for 5 min. DA release was evoked by an optic fiber that delivered a 4 ms pulse of 10 mW blue light (473 nm) every 4 min. The first 5 stable recordings (within ± 20% nA of average) were averaged as baseline with subsequent recordings expressed as percent change of baseline measurements. Drugs dissolved in Krebs buffer were perfused immediately following the 5^th^ baseline recording for 10 subsequent recordings. Averaged baseline currents were compared with averaged recordings from the last five recordings. Due to the fleeting responses when activating Pf afferents, the first two recordings were averaged as baseline, with drugs perfused immediately following the second recording. After a 16 min perfusion period, two additional recordings were collected and averaged. Following recording, electrodes were calibrated with 500-1000 nM DA dissolved in Krebs buffer using a microfluidic flow cell ([@R38]).

### Behavioral Experiments {#S16}

All testing was performed during the light phase, following 2-3 sessions of 15 min exposure to testing chambers.

### oICSS {#S17}

Food-restricted animals (90% of *ad libitum* body weight) expressing ChR2-eYFP or eYFP in the rILN were trained to lever press in a 21.6 × 17.8 × 12.7 cm operant chamber containing two retractable levers separated by a trough pellet receptacle. Pressing on either lever was reinforced with a 14 mg purified sucrose pellet (Bio-Serv) delivered on a fixed rate of one pellet per press (FR1). Mice were trained in twice-daily 30 min sessions. Once trained to lever press at least 30 times per session for 6 consecutive sessions, mice completed a single 30 min oICSS session (Day 1) in which a press on the non-biased lever (as determined from training sessions) initiated bilateral delivery of 5 Hz light for 1 s to the DS ([Figure 4A](#F4){ref-type="fig"}). 24 hr later, light activation was paired with the opposite lever in a second oICSS session (Day 2). To test the role of DA D1 receptor signaling in rILN oICSS, mice were injected with either 0.055 mg/kg SCH23390 dissolved in 0.9% NaCl (SCH) or vehicle (Veh; 10 ml/kg *i.p.*) 30 min prior to both Day 1 and 2 test sessions. To assess the effect of drug injection (SCH or Veh) alone on motor performance, mice also completed the 2-day oICSS protocol in which presses on neither lever delivered light (No Light). Thus, each animal completed four counter-balanced oICSS tests (Veh+Light, SCH+Light, Veh+No Light, and SCH+No Light) separated by 6 FR1 food-reinforced sessions. Patch cables, connected to a commutator and 465 nm LED module (Plexon), were attached to optic fiber implants via ceramic sleeves (Thorlabs).

### Open Field Assay {#S18}

Mice expressing GCaMP6f in substantia nigra DA neurons and hM4Di-mCherry or mCherry alone in rILN were assessed for movement-related nigrostriatal DA terminal activity in an open arena (70 × 30 × 25 cm). Mice were injected with vehicle solution (Veh; 0.9% NaCl, 10 ml/kg *i.p.*) 40 min prior to testing. 24 hr later, mice were administered CNO (5 mg/kg *i.p.*) 40 min prior to a second open field test. Mice were video recorded for movement analysis using Ethovision XT.

### Fiber Photometry {#S19}

Time-correlated single-photon counting fiber photometry (TCSPC; [@R45]) was used to record activity-dependent calcium signals of dopaminergic nigrostriatal terminals. 20 MHz-pulsed blue light emitted from a 473-nm picosecond diode laser (Becker & Hickl) was transmitted into a multimode fiber patchcord (RJPSL2; Thorlabs) attached to a chronic fiber implant in the DS. GCaMP6f emission photons were band-pass filtered, and transmitted into a 16-channel, 106 nm wavelength photomultiplier tube (PML-16-1-C; Becker & Hickl). Photons per channel were recorded with a TCSPC module (SPC-130-EM; Becker & Hickl). The "peak signal" was derived from the photon counts from the spectral channel corresponding to maximum GCaMP6f emission following subtraction of photons from a non-GCaMP6f -related channel.

### Immunohistochemistry {#S20}

Mice were transcardially perfused with room-temperature 0.1 M Phosphate Buffered Saline (PBS), pH 7.3, followed by ice-cold 4% (w/v) paraformaldehyde in PBS. Brains were extracted and post-fixed with 4% paraformaldehyde in PBS at 4°C. 50 μm coronal sections were cut using an Integraslice 7550 MM vibrating microtome (Campden Instruments). Chicken or goat anti-GFP and chicken anti-mCherry antibodies were used at a 1:2000 dilution. Goat anti-choline acetyltransferase antibody was used at 1:200. Secondary donkey anti-goat or anti-chicken antibodies conjugated to either Alexa 488 or 594 were used at 1:1000 dilution. The Brain BLAQ protocol ([@R26]) was used for immunohistochemistry following FSCV and electrophysiology.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S21}
---------------------------------------

All statistical analyses were performed in Prism 6.01 and are reported in the Results. The specific statistical test as well as value and description of n are listed in the figure legends. Photon counts derived from the fiber photometry experiment were analyzed in RStudio 1.1.456 prior to statistical analysis.
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![Thalamic rILN Activate Striatal Cholinergic Interneurons\
(A) Schematic of experimental approach.\
(B) Representative expression of channelrhodopsin (ChR2)-eYFP at the rostral intralaminar nuclei of the thalamus (rILN) injection site.\
(C) Representative expression of ChR2-eYFP in rILN axon terminals (green) and cholinergic interneurons (red) in the dorsal striatum (DS).\
(D) Recorded tdTomato-expressing cholinergic interneuron.\
(E) Sample trace of a cell-attached cholinergic interneuron recording.\
(F) Left: NBQX and AP5 application reduced the average peak amplitude of post-synaptic currents evoked by optogenetic activation (oPSCs; one 2--4 ms pulse, blue bar) of ChR2-expressing rILN terminals (orange; n = 6 cells) versus control aCSF (gray; n = 4 cells). Right: representative oPSCs: control (black), after incubation in aCSF (gray), or NBQX and AP5 (orange).\
(G) Top: representative whole-cell current-clamp recording of burst firing in a cholinergic interneuron in response to optogenetic rILN terminal activation (15 pulses at 10 Hz), followed by a firing pause. Middle: representative raster plots of six consecutive responses. Bottom: corresponding histogram of average firing per second.\
(H) Time to first spike following burst firing was greater than the average interspike interval (ISI) during tonic firing (n = 11 cells).\
(I) Representative cholinergic interneuron recording following incubation in 5 μM sulpiride (top), with a raster plot of six consecutive responses (middle) and corresponding histogram (bottom).\
(J--M) Comparison of cholinergic interneuron burst-pause firing properties between control (n = 12 cells) and in sulpiride (n = 12 cells) of (J) baseline firing rate, (K) burst firing rate, (L) post-burst-pause length, and (M) ratio of post-burst ISI to mean baseline ISI.\
aCSF, artificial cerebral spinal fluid; cc, corpus callosum; fr, fasciculus retroflexus. Scale bars: 250 μm (B and C) and 40 μm (D). Unpaired t test (F); Wilcoxon signed-rank test (H); Mann-Whitney test (J--M): \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001. Individual values are represented in gray or orange, with mean ± SEM in black.](nihms-1520900-f0002){#F1}

![rILN Afferent Activation Evokes DA Release in the DS\
(A) Approach for fast-scan cyclic voltammetry (FSCV) recordings.\
(B) Left: optogenetic rILN terminal activation in the DS elicited a dopamine (DA) current with a corresponding cyclic voltammogram (top) and a plot of the background-subtracted current (bottom). Right: representative electrode calibration of the current to known DA concentrations (3--4 recordings per concentration).\
(C) DA release time course in control (black; n = 8 recordings) and following NBQX application (orange; n = 8 slices).\
(D) AP5 (orange) did not alter rILN-induced DA release (n = 8 slices).\
(E) Mecamylamine (orange) abolished DA release (n = 8 slices).\
(F) Quinpirole (orange) eliminated DA release (n = 7 slices).\
Unpaired t test (C--F): \*\*\*\*p \< 0.0001. Data represent mean ± SEM.](nihms-1520900-f0003){#F2}

![Chemogenetic Suppression of rILN Firing Decreases Dopaminergic Nigrostriatal Terminal Activity and Locomotion\
(A) Approach for chemogenetic rILN terminal inhibition and synaptic transmission interrogation.\
(B) Left: recording from DS medium spiny neurons (MSNs) in striatal slices; application of clozapine-N-oxide (CNO; red) attenuated rILN-evoked oPSC amplitude (n = 6 cells) as compared to control aCSF (gray; n = 9 cells). Right: representative oPSC traces, before (black) and after aCSF (gray) or CNO (red) incubation.\
(C) Left: experimental strategy to chemogenetically suppress rILN activity and monitor dopaminergic nigrostriatal terminal activity. Middle: timeline of drug administration and behavioral testing. Right: representative expression of GCaMP6f (green) in the substantia nigra (SN).\
(D) Emission profile of GCaMP6f in the DS, with the peak GCaMP6f channel (white arrow) and off-peak channel (gray arrow).\
(E) Left: representative traces of the peak signal in hM4Di and mCherry-expressing mice moving freely in an open field following vehicle (Veh; black) or CNO (blue; 5 mg/kg) injection. Right: average peak signal was decreased in hM4Di-expressing mice (N = 16 mice), but not mCherry-expressing mice (N = 14 mice), by CNO.\
(F--H) Changes in movement between groups: (F) total distance traveled, (G) maximum velocity, and (H) percentage of time in motion.\
Scale bar: 250 μm. Unpaired t test (B); post hoc Holm-Šidàk test (E--H): \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. Individual values are represented in gray; data represent mean ± SEM.](nihms-1520900-f0004){#F3}

![Optogenetic Activation of rILN Afferents in the DS Is Reinforcing\
(A) Top left: approach for *in vivo* optogenetic rILN-terminal activation and ChR2-eYFP expression relative to fiber placement in DS. Right and bottom left: experimental timeline and procedure for a two-day optical intracranial self-stimulation paradigm (oICSS).\
(B) ChR2-eYFP-expressing mice pressed the light-paired lever (blue fill) more than the non-reinforced lever (black fill) in a light and DA D1 receptor-dependent manner.\
(C) eYFP-expressing mice did not press the light-paired lever more than the non-reinforced lever (N = 9 mice).\
(D) Left: strategy to ablate DS cholinergic interneurons at site of light delivery. Right: representative taCasp3-mediated ablation of cholinergic interneurons (red) and expression of ChR2-eYFP-expressing rILN terminals (green) in the DS.\
(E) mCherry-expressing mice (N = 7) pressed the light-paired lever (blue) more than the non-reinforced lever (black) on both test days. taCasp3-ablated mice (N = 6) only pressed the light-paired lever more on day 2.\
FR1, fixed-rate 1; SCH, SCH23390. Scale bars = 250 μm. Post hoc Holm-Šidàk test: \*p \< 0.05, \*\*p \< 0.01, \*\*\*\*p \< 0.0001. Individual values are represented in gray; data represent mean ± SEM.\
See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms-1520900-f0005){#F4}

###### 

KEY RESOURCES TABLE

  Reagent or Resource                             Source                                Identifier
  ----------------------------------------------- ------------------------------------- --------------------------------
  Antibodies                                                                            
  Chicken anti-GFP                                Abcam                                 \#ab13970;RRID:AB_300798
  Goat anti-GFP                                   Abcam                                 \#ab6673; RRID:AB_305643
  Chicken anti-mCherry                            Novus Biologicals                     \#NBP2-25158; RRID:AB_2636881
  Alexa 488 Donkey anti-Goat                      Jackson ImmunoResearch                \#705-545-003; RRID:AB_2340428
  Alexa 488 Donkey anti-Chicken                   Jackson ImmunoResearch                \#703-545-155; RRID:AB_2340375
  Alexa 594 Donkey anti-Goat                      Jackson ImmunoResearch                \#705-585-147; RRID:AB_2340433
  Alexa 594 Donkey anti-Chicken                   Jackson ImmunoResearch                \#703-585-155; RRID:AB_2340377
  Goat anti-Choline Acetyltransferase             Novus Biologicals                     \#NBP1-30052; RRID:AB_1968484
  Bacterial and Virus Strains                                                           
  AAV5-hSyn-hChR2(H134R)-eYFP                     Karl Deisseroth / Addgene             26973-AAV5
  AAV5-hSyn-eYFP                                  Karl Deisseroth / UNC Vector Core     N/A
  AAV5-hSyn-GCaMP6f-FLEX                          [@R8] / Addgene                       100833-AAV5
  AAV8-hSyn-hM4Di-mCherry                         Bryan Roth / Duke Viral Vector Core   N/A
  AAV5-flex-taCasp3-TEVp                          Nirao Shah / UNC Vector Core          N/A
  AAV5-EF1a-DIO-mCherry                           Karl Deisseroth / UNC Vector Core     N/A
  AAV8-hSyn-mCherry                               Karl Deisseroth / UNC Vector Core     N/A
  Chemicals, Peptides, and Recombinant Proteins                                         
  Clozapine-N-oxide                               Abcam                                 \#ab141704
  DL-AP5 sodium salt                              Abcam                                 \#ab120271
  Mecamylamine hydrochloride                      Tocris Bioscience                     \#2843
  NBQX disodium salt                              Abcam                                 \#ab120046
  (−)-Quinpirole hydrochloride                    Tocris Bioscience                     \#1061
  R(+)-SCH23390 hydrochloride                     Sigma-Aldrich                         \#D054
  (RS)-(±)-Sulpiride                              Tocris Bioscience                     \#0894
  Experimental Models: Organisms/Strains                                                
  Mouse, C57BL/6J                                 Jackson Laboratory                    \#000664
  Mouse, ChAT-IRES-Cre                            Jackson Laboratory                    \#028861
  Mouse, Ai9(RCL-tdT)                             Jackson Laboratory                    \#007909
  Mouse, DAT-IRES-Cre                             Jackson Laboratory                    \#006660
  Software and Algorithms                                                               
  Data analysis: Prism 6.01                       Graphpad                              <https://www.graphpad.com/>
  Data analysis: RStudio 1.1.456                  RStudio                               <https://www.rstudio.com/>
  MedPC-IV 4.2                                    Med Associates                        SOF-735
  Ethovision XT v11.5                             Noldus                                <https://www.noldus.com/>
  Other                                                                                 
  Operant Chamber                                 Med Associates                        ENV-307W

###### Highlights

-   The rostral intralaminar nuclei of the thalamus (rILN) project to the dorsal striatum

-   Glutamatergic rILN projections induce local dopamine release in the dorsal striatum

-   rILN activity suppression correlates with reduced nigrostriatal activity and movement

-   rILN terminal activation supports behavioral reinforcement
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